Alto Neuroscience jumps after plans to accelerate depression drug development

Alto Neuroscience

20/10/2025 15:02

Updates

** Shares of drug developer Alto Neuroscience ANRO.N rise 50% to $9.12

** Company says it plans to accelerate the development of its experimental drug, ALTO-207, for people with treatment-resistant depression

** Treatment-resistant depression is a type of major depressive disorder where symptoms do not improve after trying at least two different antidepressant medications at adequate doses and for sufficient time

** The $50 million private placement announced earlier today supports expanded development of ALTO-207 - ANRO

** Company expects to begin late-stage study by early 2027

** Jefferies thinks this reduces some risk around the ongoing mid-stage trial of ALTO-101 in bipolar depression, since the company believes its earlier study in major depression failed partly due to patients not sticking to the treatment

** Jefferies estimates a potential approval of ALTO-207 as early as 2030

** Including session moves, stock up 81.1% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))